CA3193194A1 - Sik inhibitors and methods of use thereof - Google Patents

Sik inhibitors and methods of use thereof

Info

Publication number
CA3193194A1
CA3193194A1 CA3193194A CA3193194A CA3193194A1 CA 3193194 A1 CA3193194 A1 CA 3193194A1 CA 3193194 A CA3193194 A CA 3193194A CA 3193194 A CA3193194 A CA 3193194A CA 3193194 A1 CA3193194 A1 CA 3193194A1
Authority
CA
Canada
Prior art keywords
substituted
compound
unsubstituted
ring
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3193194A
Other languages
English (en)
French (fr)
Inventor
Braham Shroot
Beatrice LE VARLET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soltego Inc
Original Assignee
Soltego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soltego Inc filed Critical Soltego Inc
Publication of CA3193194A1 publication Critical patent/CA3193194A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3193194A 2020-09-21 2021-09-21 Sik inhibitors and methods of use thereof Pending CA3193194A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063081089P 2020-09-21 2020-09-21
US63/081,089 2020-09-21
PCT/US2021/051375 WO2022061312A1 (en) 2020-09-21 2021-09-21 Sik inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3193194A1 true CA3193194A1 (en) 2022-03-24

Family

ID=80775691

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3193194A Pending CA3193194A1 (en) 2020-09-21 2021-09-21 Sik inhibitors and methods of use thereof

Country Status (7)

Country Link
US (1) US20230265099A1 (https=)
EP (1) EP4213851A4 (https=)
JP (1) JP2023544446A (https=)
CN (1) CN117136061A (https=)
AU (1) AU2021343539A1 (https=)
CA (1) CA3193194A1 (https=)
WO (1) WO2022061312A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4526307A1 (en) * 2022-05-17 2025-03-26 Soltego, Inc. Pyrimidopyrimidone compounds and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
WO2018009544A1 (en) * 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) * 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
AU2018226771B2 (en) * 2017-02-28 2023-11-23 Dana-Farber Cancer Institute, Inc. Uses of pyrimidopyrimidinones as SIK inhibitors
CA3124574A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
AU2021262482A1 (en) * 2020-04-28 2023-01-05 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2022061312A1 (en) 2022-03-24
EP4213851A4 (en) 2025-08-06
CN117136061A (zh) 2023-11-28
AU2021343539A9 (en) 2024-09-26
AU2021343539A1 (en) 2023-05-18
US20230265099A1 (en) 2023-08-24
EP4213851A1 (en) 2023-07-26
JP2023544446A (ja) 2023-10-23

Similar Documents

Publication Publication Date Title
AU2018226771B2 (en) Uses of pyrimidopyrimidinones as SIK inhibitors
JP6728321B2 (ja) 置換ピリミジンＢｍｉ−１阻害剤
CA2952083C (en) Substituted urea derivatives and pharmaceutical uses thereof
CA2872979C (en) Macrocyclic compounds as protein kinase inhibitors
US9511067B2 (en) Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels
KR101839915B1 (ko) 아릴아미노 퓨린 유도체, 그의 제조 방법 및 약학적 용도
CN108495628B (zh) 苯并噻吩基选择性雌激素受体下调剂
EA035349B1 (ru) ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
JP7050093B2 (ja) 置換５員および６員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用
WO2018176343A1 (en) Bicyclic heteroaryl derivatives and preparation and uses thereof
MX2014015024A (es) Dihidronaftiridinas y compuestos relacionados útiles como inhibidores de cinasas para el tratamiento de enfermedades proliferativas.
AU2019299234A1 (en) PIKfyve inhibitors
CA2693062A1 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
EP2925747B1 (en) Azaquinazoline carboxamide derivatives
WO2018209239A1 (en) Potent agelastatin derivatives as modulators for cancer invasion and metastasis
KR102369925B1 (ko) 구조적으로 제한된 PI3K 및 mTOR 억제제
CA3193194A1 (en) Sik inhibitors and methods of use thereof
AU2019267554A1 (en) Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof
KR20200035990A (ko) 신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도
CN102070555A (zh) 3-(2-氨基-乙基)-5-(3-环己基-亚丙基)-噻唑啉-2，4-二酮及其衍生物
KR101158568B1 (ko) 신경발생을 자극 및 신경 퇴화를 억제하는 방법 및 조성물
CN110730782B (zh) 光动力治疗化合物和光动力治疗方法
CN115466260B (zh) 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用
BR112020009855A2 (pt) tratamento de distúrbios de pele
JP2003502362A (ja) 化学療法および／または放射線療法の副作用の苛酷さを防止／軽減するための組成物および方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250915

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250922

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250922

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251124

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251124

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251124

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251124